IMU is a $465mn clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. Clearly an exciting prospect for all human kind, but a complicated, costly and uncertain pathway that has weighed on the stock in recent years, tumbling ~90% from its 2021 high. Last month IMU raised capital at 8.4c with the buyers already significantly underwater, excuse the throwaway line but this stock is simply too hard and it reminds us again why investing in Biotech is not for the faint-hearted.
Health Biotech IMU manufacturers vaccines for gastric and breast cancer, it may look / feel like a “penny dreadful” trading at 17c but it does have a market cap of almost $1bn. This is a ‘risk on’ stock and is only likely to rally when the market feels confident enough to take on risk. Right now, it’s a coin toss to guess where it could end although the company has $100mn in cash and a number of promising trials...
IMU is a $1.6bn biotech that’s also more than halved over the last 6-months, its been a sorry tale across the sector. The business manufactures vaccines for gastric and breast cancers and we believe its recent collaboration with giant Merck & CO. is very encouraging providing a degree of confidence to accumulate into current weakness.
Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required